About Deep Genomics
The Problem Deep Genomics addresses a core startup pain point: fragmented operations, slow decision cycles, and poor visibility across teams. Organizations in this market often rely on disconnected tools, which creates delays, revenue leakage, and inconsistent customer outcomes.
The Solution Deep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies. Artificial Intelligence Biotech Healthcare In practice, Deep Genomics centralizes critical workflows, automates repetitive coordination, and gives operators a real-time system of record. This reduces manual overhead and improves execution quality at scale.
Why it's growing With the rise of shifting customer expectations, faster digital adoption, and demand for measurable ROI, Deep Genomics is positioned to capture sustained demand. Buyers now prioritize speed, reliability, and clear ROI, and the company aligns directly with those purchasing criteria.
Culture The team operates in a fast-paced environment focused on startup innovation, product velocity, and customer-centric execution. Their culture emphasizes ownership, experimentation, and measurable outcomes.
Why it Matters
Deep Genomics matters now because with the rise of shifting customer expectations, faster digital adoption, and demand for measurable ROI, Deep Genomics is positioned to capture sustained demand. Buyers now prioritize speed, reliability, and clear ROI, and the company aligns directly with those purchasing criteria.
Funding Snapshot
- Series C • Khosla Ventures, $180M Series C in 2021, $720M valuation
Hiring Roles
This company is actively hiring.
Meet the Founders
Deep Genomics Team
Founder & CEO